These studies will also be crucial in identifying any long-term renal risks associated with semaglutide use, ensuring a balanced and informed approach to its prescription
Neither BPC-157 or TB-500, the two compounds in REGEN, are approved by Health Canada
Common: Nausea, vomiting, diarrhea, or constipation Reduced appetite (sometimes too much) Mild low blood sugar (especially with other diabetes medications) Injection site reactions Less common but serious: Pancreatitis Gallbladder issues Kidney complications from dehydration Thyroid tumors (observed in rodent studies and still under investigation in humans) This is a non-exhaustive list
The Precision Peptide Genetic Test examines 14 metabolic pathways and 49 peptides, including key variants in GIPR, GLP1R, FTO, and MC4R genes that influence your response to GLP-1 therapy and appetite regulation
Fatemi SA, Alqhtani A, Elliott K, Bello A, Zhang H, Peebles ED